Valuation: Tarsus Pharmaceuticals, Inc.

Market Cap 3.05B 2.72B 2.52B 2.29B 4.3B 289B 4.37B 30.21B 11.88B 151B 11.44B 11.2B 483B P/E 2026 *
-14.5x
P/E 2027 * 521x
Enterprise Value 2.71B 2.42B 2.24B 2.04B 3.82B 257B 3.89B 26.88B 10.57B 134B 10.18B 9.97B 430B EV / Sales 2026 *
3.73x
EV / Sales 2027 * 2.8x
Free-Float
97.31%
Yield 2026 *
-
Yield 2027 * -
1 day+2.49%
1 week+0.32%
Current month-9.62%
1 month-8.28%
3 months+26.31%
6 months+7.70%
Current year-13.23%
1 week 67.93
Extreme 67.93
74.94
1 month 67.93
Extreme 67.93
79.1
Current year 53.89
Extreme 53.89
91.53
1 year 53.89
Extreme 53.89
91.53
3 years 12.84
Extreme 12.84
91.53
5 years 10.8
Extreme 10.8001
91.53
10 years 10.8
Extreme 10.8001
91.53
Manager TitleAgeSince
Chief Executive Officer 48 2018-08-31
Director of Finance/CFO 64 2023-04-23
Chief Tech/Sci/R&D Officer 47 2024-11-03
Director TitleAgeSince
Chairman 48 2022-12-01
Director/Board Member 71 2019-11-30
Director/Board Member 80 2016-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/15/26 Exercice

Director

604 0.0014%
9/15/26 Exercice

Director

12,902 0.0294%
9/15/26 Exercice

Director

402 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+3.26%+0.32%-0.20%+441.95% 3.05B
+4.80%+11.55%+60.85%+122.57% 1,106B
+2.60%+4.22%+33.75%+69.35% 612B
+2.17%+4.88%+23.99%+96.77% 500B
+2.41%+8.17%+38.46%+62.85% 367B
+3.29%+4.28%+71.52%+44.20% 354B
+1.63%+5.45%+20.80%+48.35% 286B
+1.52%+5.36%-0.24%+20.17% 256B
+2.59%+5.32%+43.34%+55.94% 230B
+1.55%+4.93%+26.07%+99.50% 190B
Average +2.30%+4.77%+31.83%+106.17% 390.32B
Weighted average by Cap. +2.81%+6.49%+41.04%+81.24%

Financials

2026 *2027 *
Net sales 727M 648M 601M 546M 1.02B 68.97B 1.04B 7.2B 2.83B 36.05B 2.73B 2.67B 115B 920M 820M 760M 691M 1.3B 87.23B 1.32B 9.11B 3.58B 45.59B 3.45B 3.38B 146B
Net income -215M -192M -177M -161M -303M -20.38B -308M -2.13B -837M -10.65B -806M -790M -34.05B 9.62M 8.57M 7.94M 7.22M 13.55M 912M 13.77M 95.27M 37.46M 477M 36.09M 35.33M 1.52B
Net Debt -336M -300M -278M -252M -474M -31.88B -482M -3.33B -1.31B -16.66B -1.26B -1.24B -53.27B -476M -424M -393M -357M -670M -45.09B -681M -4.71B -1.85B -23.57B -1.78B -1.75B -75.34B
Projected Income Statement - Annual - Tarsus Pharmaceuticals, Inc.
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic.
Employees
370
Date Price Change Volume
26-10-20 $71.05 +2.23% 82,079
26-10-19 $69.50 +2.10% 682,551
26-10-16 $68.07 -4.11% 2,871,594
26-10-15 $70.99 -1.80% 1,398,351
26-10-14 $72.29 +2.08% 1,166,768
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Tarsus Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
69.50USD
Average target price
99.80USD
Spread / Average Target
+43.60%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Tarsus Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. TARS Stock